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Objective: To investigate the therapeutic effect and the related mechanism of oridonin
on mice with prostate cancer.
Methods: Sixty BALB/C male nude mice were selected. A model of RM-1 cell trans-
plantation tumor of prostate cancer was built by the subcutaneous inoculation of RM-
1 cells. After that, those 60 experimental mice were randomly divided into groups A, B
and C. Each group had 20 mice. Mice in group A were treated with 0.2 mL of normal
saline (0.9%) by intraperitoneal injection once a day; mice in group B received intra-
peritoneal injection of 1.875 mg/mL of oridonin once a day; and mice in group C received
intraperitoneal injection of 7.5 mg/mL of oridonin once a day. Mice in the three groups
were treated uninterruptedly for 5 weeks and were all killed. Then, tumors were excised
and weighed to calculate their growth inhibitory rate, volume increment and anti-tumor
rate. Thymus and spleen of mice in the three groups were collected to calculate the
thymus and spleen index. Immunohistochemical staining was applied to observe the
expression of caspase-3 in prostate cancer tissue of mice of the three groups.
Results: The qualities and volume increment of tumors in groups B and C were
signiﬁcantly lower than those of group A (P < 0.05); the qualities and volume increment
of tumors in groups C were evidently lower than those of group B (P < 0.05); the tumor
volume increment and anti-tumor rate in group C were obviously higher than those of
group B (P < 0.05); the thymus and spleen indexes of groups B and C were distinctly
higher than those of group A (P < 0.05); comparison of the thymus and spleen indexes
between group B and group C showed no statistical differences (P > 0.05). Immumo-
histochemical staining revealed that the caspase-3 protein in prostate cancer tissue of mice
of group A expressed negatively with colorless or light-colored karyon; while the
caspase-3 protein in prostate cancer tissue of mice of group B expressed positively with
dark-colored karyon, centralized distribution and granular sensation; and the caspase-3 in
prostate cancer tissue of mice of group C showed strong positive expression with big and
darker colored karyon and dense distribution.
Conclusions: Oridonin can inhibit the growth of RM-1 prostate cancer cells effectively
and have great therapeutic effects on RM-1 cell transplantation tumor of prostate cancer.1. Introduction
Prostate cancer, which is a common malignant disease in
male, refers to a kind of epithelial malignant tumors occurring in
prostate. Generally, it occurs frequently in males aged over 55years and its morbidity increases with age [1–3]. According to
some statistics, the morbidity of prostate cancer tops the list of
male malignant cancers and its mortality ranks only second to
lung cancer, which is severely threatening men's health [4].
The pathogenesis of prostate cancer is related to genetic
factor, dietary habit and sex activity. Since the pathogenesis of
the disease is concealed, the disease has progressed to its
middle or advanced stage when it is diagnosed. The tumor
cells have already transferred to other organs leading to the
missing opportunity of radical operation [5–8]. Therefore, it is
signiﬁcant to ﬁnd effective drugs to prolong the survival time
and promote the life quality for patients. Oridonin is an-NC-ND license (http://
Table 1
Comparison of tumor growth inhibition rates in different treatment pe-
riods of three groups.
Group n One week Three weeks Five weeks
A 20 – – –
B 20 19.10 ± 9.48 30.09 ± 1.19 36.47 ± 3.30
C 20 52.16 ± 2.05# 63.07 ± 1.71# 69.60 ± 3.40#
Compared with group B, #P < 0.05.
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rubescens. It possesses the abilities to eliminate various cancer
cells and ﬁght against cancers and tumors effectively [9]. In
this study, in order to investigate the therapeutic effect and the
related mechanism of oridonin on mice with prostate cancer,
60 BALB/C male nude mice were selected to build a model of
RM-1 cell transplantation tumor of prostate cancer, and treated
with oridonin in different concentrations. Now the research
results were reported as follows.
2. Materials and methods
2.1. Experimental animals
Sixty 6-month-old BALB/C male nude mice (clean animal)
with weights of 18–20 g were chose. They were purchased from
Beijing Lihua Experimental Animal Technology Co. Ltd. Those
mice took food and drank freely under the room temperature of
(23 ± 3) C. The disposition of the experimental animals was
strictly abided by the laboratory animal administration rules.
2.2. Drugs and instruments
RM-1 prostate cancer cell strains were provided by Yanyu
Biotechnology Co. Ltd. (Shanghai); oridonin was bought from
Xi'an Hao Xuan Biological Technology Co. Ltd.; MTT and
Trizol were from Baotaike Company; IMDM nutrient medium
was from Gibeo (USA); Olympus invert microscope was from
Japan; Bio-rad microplate reader was from USA and Shimadzu
ultraviolet spectrophotometer was from Australia. Oridonin was
diluted by normal saline into two concentration gradients, 1.875
and 7.5 mg/mL respectively.
2.3. Model establishment
The revived RM-1 prostate cancer cells were inoculated in the
IMDM nutrient medium and then it was cultured and generated in
a 5%CO2 humidity incubator under the temperature of 37 C. The
logarithmic growth phase cells were collected and prepared into
cell suspension with the concentration of 107 cells/mL.
2.4. Animal grouping
In order to establish the model of RM-1 cell transplantation
tumor of prostate cancer, 0.2 mL of the prepared cell suspension of
RM-1 prostate cancer cells was inoculated subcutaneously in the
axilla of those experimental mice. The tumors formed successfully
in all the experimental mice. After inoculation, those mice were
randomly divided into groupsA,B andC. Each group had 20mice.
Mice in group A were treated with 0.2 mL of normal saline (0.9%)
by intraperitoneal injection once a day; mice in group B received
intraperitoneal injection of 1.875 mg/mL of oridonin once a day;
and mice in group C received intraperitoneal injection of 7.5 mg/
mL of oridonin once a day. Mice in the three groups were treated
uninterruptedly for 5 weeks.
2.5. Observation
During the ﬁrst, third and ﬁfth weeks after inoculation, ver-
nier caliper was used to measure the tumor volume and draw the
tumor growth curves. Then, those mice were all killed afterﬁnishing the treatment. And the tumors were excised and
weighed to calculate their growth inhibitory rate, volume
increment and anti-tumor rate. Thymus and spleen of mice were
collected to calculate the thymus and spleen index. Immumo-
histochemical staining was applied to observe the expression of
caspase-3 in prostate cancer tissue of mice of the three groups.
2.6. Statistical arrangement
SPSS 10.0 was used to analyze research data and mean ± SD
was applied to express the tumor volume, volume increment and
anti-tumor rate, etc. One-way ANOVA was used for intergroup
comparison. Differences indicated statistical signiﬁcances when
P < 0.05.
3. Results
3.1. Comparison of tumor growth inhibition rates in
different treatment periods of three groups
Since tumors in mice of group A grew continuously in all
treatment periods, the tumor growth inhibition rate of group A
was ignored. The tumor growth inhibition rates of group C for 1,
3 and 5 weeks were all higher than those of group B.
Comparative differences between groups had statistical signiﬁ-
cances (P < 0.05) (Table 1).
3.2. Comparison of qualities, volumes, volume
increments of tumors and anti-tumor rates of three
groups
The quality and volume increment of tumors in groups B and
C were signiﬁcantly lower than those of group A, and the
comparative differences between groups had statistical signiﬁ-
cances (P < 0.05); the qualities and volume increment of tumors
in groups C were evidently lower than those of group B and the
tumor volume increment and anti-tumor rate in group C were
obviously higher than those of group B, and the comparative
differences between groups also showed statistical signiﬁcances
(P < 0.05) (Table 2).
3.3. Comparison of thymus and spleen index of mice in
three groups
The thymus and spleen indexes of groups B and C were
distinctly higher than those of group A, and comparative dif-
ferences between groups had statistical signiﬁcances (P < 0.05);
while comparison of the thymus and spleen indexes between
group B and group C showed no statistical differences
(P > 0.05) (Table 3).
Table 2
Comparison of qualities, volumes, volume increments of tumors and anti-tumor rates of three groups.
Group n Tumor
quantity (g)
Tumor
volume (mm2)
Tumor
volume
increment
Anti-tumor
rate (%)
A 20 2.75 ± 1.61 163.58 ± 58.84 0.10 ± 0.04 –
B 20 1.80 ± 0.95* 86.93 ± 33.24 0.07 ± 0.04* 34.1
C 20 0.90 ± 0.22*# 68.44 ± 39.48 0.04 ± 0.01*# 66.8#
Compared with group A, *P < 0.05; Compared with group B, #P < 0.05.
Table 3
Comparison of thymus and spleen index of mice in three groups.
Group n Thymus index Spleen index
A 20 2.01 ± 0.53 10.22 ± 1.96
B 20 3.93 ± 0.33* 12.92 ± 0.43*
C 20 4.02 ± 0.41* 13.03 ± 0.89*
Compared with group A, *P < 0.05.
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cancer tissue of mice of three groups
The caspase-3 protein in prostate cancer tissue of mice of
group A expressed negatively with colorless or light-colored
karyon; while the caspase-3 protein in prostate cancer tissue of
mice of group B expressed positively with dark-colored karyon,
centralized distribution and granular sensation; and the caspase-
3 in prostate cancer tissue of mice of group C showed strong
positive expression with big and darker colored karyon and
dense distribution.
4. Discussion
Prostatic cancer is a common malignant disease in male
urology department and its mortality rate ranks only second to
lung cancer, which can bring great harm to patients' health. The
morbidity rate of prostatic cancer is lower in people under 55
years old and it increases with age. The peak stage of prostatic
cancer prevalence is from 70 to 80 years old. In recent year, the
incidence of prostatic cancer increased year by year due to the
aging population trend [10–15]. The main pathological types of
prostatic cancer include adenocarcinoma, urothelium
carcinoma, ductal adenocarcinoma, adenosquamous carcinoma
and squamous-cell carcinoma. Among them, the adenocarci-
noma accounts for more than 95% of pathogenesis of prostatic
cancer [2,16–21]. Since the pathogenesis of the disease is
concealed, the disease has progressed to its middle or
advanced stage when it is diagnosed. The tumor cells have
already transferred leading to the missing opportunity of
radical operation. Hence, it is meaningful to search the
effective drug for patients with prostatic cancer.
Oridonin is an effective active ingredient extracted from
natural Rabdosia rubescens and it can exterminate various
cancer cells effectively. Oridonin are mainly clinically applied in
anti-cancer, anti-bacterial, anti-tumor, insecticide, heat-clearing
and detoxifying, anti-inﬂammatory and analgesics, invigorating
the stomach and activating blood treatment, etc. There were
researches showing that oridonin has a signiﬁcant inhibitory
effect on prostatic cancer and breast cancer by inhibiting thein vitro proliferation and invasion of lung cancer A549 and PC9
cells to restrain the tumor [22,23]. In this study, oridonin with
different doses were used to treat RM-1 cell transplantation
tumor in mice with prostatic cancer by intraperitoneal injection
and found that the tumor growth inhibiting rate at different
treatment periods of mice in group C was signiﬁcantly higher
than those of group B (P < 0.05), which indicated that the
megadose of oridonin has a more positive effect on RM-1 cell
transplantation tumor of prostatic cancer treatment. The quality
and volume increment of tumors in groups B and C were
signiﬁcantly lower than those of group A (P < 0.05) after the
termination of treatment in this study, and the quality and
volume increment of tumors in group C were signiﬁcantly
lower than those of group B (P < 0.05) and the volume
increment of tumor and anti-tumor rate of group C were
signiﬁcantly higher than those of group B (P < 0.05), which also
conﬁrmed that oridonin has a signiﬁcantly inhibitory effect on
the growth and proliferation of RM-1 cell transplantation tumor
in prostatic cancer. The thymus and spleen are the most
important immune organs in human body and they can inhibit
body's immune function by various approaches to provide an
immunosuppressive state for hosts when tumors occur. Thus, the
indexes of immune organs are used as indicators to measure the
of body's immune function [24]. In this study, the indexes of
thymus and spleen in groups B and C were signiﬁcantly
higher than those of group A (P < 0.05), which indicated that
oridonin can improve the immune function in mice with
prostatic cancer.
Some studies have shown that apoptosis is a programmed
death regulated by gene [24–27], and there are three signal channels
participating in the progress of apoptosis. Besides, some other
studies have conﬁrmed that caspase is the core of apoptosis and
caspase-3, caspase-6 and caspase-7 participate in the effective
stage of apoptosis, while caspase-3 is the major executive in the
apoptosis [28,29]. In this research, immumohistochemical
staining revealed that the caspase-3 protein in prostate cancer
tissue of mice of group C showed strong positive expression with
big and darker colored karyon and dense distribution, which
showed that oridonin can cause the cascade reaction of caspase
substrate and induce apoptosis of transplantation tumor to inhibit
the tumor by activating caspase-3.
The results of this study showed that oridonin can effectively
inhibit the growth of RM-1 cells of prostatic cancer and has a
signiﬁcantly therapeutic effect on prostatic cancer.
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